Your search for oral corticosteroids returned 138 results

The FDA has approved Zeposia® (ozanimod) for moderately to severely active ulcerative colitis in adults.

Long-term treatment of oral corticosteroid (OCS)-dependent asthma with dupilumab has shown efficacy in weaning off OCS while improving lung function.

Patients with normal adrenal function are largely able to eliminate the use of oral corticosteroids or achieve a daily dose of 5 mg or less.

The BLA submission is supported by data from the PATHFINDER clinical program.

Previous studies have shown that GLP-1RAs demonstrate a protective effect by attenuating bronchial hyperresponsiveness.

Ascorbic acid level testing confirmed severe deficiency (<0.1mg/dL).

The submission was based on data from the double-blind, placebo-controlled VOYAGE trial.

Patients with asthma who depend on oral corticosteroids (OCS) may be able to reduce the dependence or eliminate the use of OCS altogether with benralizumab.

Active eosinophilic esophagitis appears to be associated with lower lung function and increased asthma severity in children with comorbid asthma.

Tezepelumab is an investigational first-in-class human monoclonal antibody that works by blocking thymic stromal lymphopoietin.